Travis Steed
Stock Analyst at Barclays
(2.65)
# 2,202
Out of 5,031 analysts
86
Total ratings
42.03%
Success rate
6.19%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $189.10 | +38.02% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $249.00 | +28.51% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $128.54 | +16.70% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $72.16 | +17.79% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $74.64 | +20.58% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $12.71 | +151.77% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $23.09 | +94.89% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $13.25 | +239.62% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $374.42 | -15.87% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $318.59 | -7.40% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $16.59 | -3.56% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $14.79 | +123.12% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $101.92 | +56.99% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $446.13 | -29.39% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.52 | +426.32% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $13.56 | +84.37% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $15.31 | +455.19% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $66.60 | +87.69% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $95.78 | +51.39% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $99.24 | -48.61% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $45.19 | +287.25% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $15.08 | +258.09% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $55.60 | -60.43% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $189.10
Upside: +38.02%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $249.00
Upside: +28.51%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $128.54
Upside: +16.70%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $72.16
Upside: +17.79%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $74.64
Upside: +20.58%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $12.71
Upside: +151.77%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $23.09
Upside: +94.89%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $13.25
Upside: +239.62%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $374.42
Upside: -15.87%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $318.59
Upside: -7.40%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $16.59
Upside: -3.56%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $14.79
Upside: +123.12%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $101.92
Upside: +56.99%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $446.13
Upside: -29.39%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.52
Upside: +426.32%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $13.56
Upside: +84.37%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $15.31
Upside: +455.19%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $66.60
Upside: +87.69%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $95.78
Upside: +51.39%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $99.24
Upside: -48.61%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $45.19
Upside: +287.25%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $15.08
Upside: +258.09%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $55.60
Upside: -60.43%